| Description | BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based
biotechnology company focused on developing and
commercialising non-invasive diagnostic tests for early detection
of cancer. BARD1s proprietary technology platform is based on
novel tumour markers with potential diagnostic and therapeutic
applications across multiple cancers. The pipeline includes two
development-stage BARD1 autoantibody tests for early detection
of lung and ovarian cancers, and a research-stage cancer vaccine
under evaluation for treatment of cancer. Additional diagnostic
projects are being evaluated for prostate, breast and other
cancers. BARD1 is committed to transforming the early detection
and prevention of cancer to help improve patients lives. BARD1 is
headquartered in Perth, Australia, and has contract research
laboratories at University of Geneva, Switzerland.
Additional info from OTC:
BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based
biotechnology company focused on developing and
commercialising non-invasive diagnostic tests for early detection
of cancer. BARD1s proprietary technology platform is based on
novel tumour markers with potential diagnostic and therapeutic
applications across multiple cancers. The pipeline includes two
development-stage BARD1 autoantibody tests for early detection
of lung and ovarian cancers, and a research-stage cancer vaccine
under evaluation for treatment of cancer. Additional diagnostic
projects are being evaluated for prostate, breast and other
cancers. BARD1 is committed to transforming the early detection
and prevention of cancer to help improve patients lives. BARD1 is
headquartered in Perth, Australia, and has contract research
laboratories at University of Geneva, Switzerland. |
|---|